All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.
The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your ALL Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
What unusual toxicities are seen in patients with ALL and what are the best strategies to manage them?
Bookmark this article
During the ALL Hub Steering Committee meeting, members discussed ongoing research to address unmet needs in the assessment and management of unusual and severe toxicities, in in both pediatric and adult acute lymphoblastic leukemia. This discussion was chaired by Kjeld Schmiegelow and featured Helene Hallböök, José María Ribera, Anita Rijneveld, André Baruchel, Oliver Ottmann, and Charles Mullighan.
What unusual toxicities are seen in patients with ALL and what are the best strategies to manage them?
The key unmet needs identified include global uniformity in the definition and management of unusual toxicities, evaluation of the long-term effects in patients experiencing toxicities, and re-exposure to novel therapies following toxicities.
More about...
Your opinion matters
15 votes - 17 days left ...
Related articles
Newsletter
Subscribe to get the best content related to ALL delivered to your inbox